NasdaqGM:CRSPBiotechs
Casgevy Uptake Grows As CRISPR Therapeutics Shares Trade Below Estimates
CRISPR Therapeutics reported a threefold increase in Casgevy patient initiations for sickle cell disease and beta thalassemia over the past year.
The company highlighted ongoing commercial rollout progress alongside continued net losses.
Management pointed to a strong cash position as support for both Casgevy expansion and further R&D.
CRISPR Therapeutics, trading on NasdaqGM:CRSP, is in the spotlight as Casgevy gains early traction in the gene therapy market. The stock closed at $57.33,...